(DNTH) Dianthus Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 4.553m USD | Total Return: 450.9% in 12m
Antibodies, Therapeutics, Autoimmune, Inflammation
Total Rating 38
Safety 42
Buy Signal 0.51
Biotechnology
Industry Rotation: +3.6
Industry Rotation: +3.6
Market Cap:
4.55B
Avg Turnover: 92.1M USD
Avg Turnover: 92.1M USD
ATR:
5.87%
Peers RS (IBD): 93.8
Peers RS (IBD): 93.8
Risk 5d forecast
Volatility70.5%
Rel. Tail Risk-14.6%
Reward TTM
Sharpe Ratio2.56
Alpha391.44
Character TTM
Beta1.093
Beta Downside0.848
Drawdowns 3y
Max DD53.48%
CAGR/Max DD1.77
Warnings
Altman Z'' -9.39 < 1.0 - financial distress zone
choppy
Tailwinds
supp_ema8
Description: DNTH Dianthus Therapeutics
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a clinical-stage biotech focused on complement-system therapeutics for severe autoimmune and inflammatory disorders, headquartered in New York and founded in 2019.
The company’s lead candidate, DNTH103-a human IgG4 monoclonal antibody that binds active C1s with picomolar affinity-is in Phase 2 trials for generalized myasthenia gravis (MG), multifocal motor neuropathy (MMN), and chronic inflammatory demyelinating polyneuropathy (CIDP). In the latest MG trial, DNTH103 achieved a statistically significant 45% improvement in MG-ADL scores versus placebo.
As of the most recent 10-Q (Q3 2025), Dianthus reported $45 million in cash and marketable securities, giving it a runway through Q2 2026, and its R&D expense grew 28% year-over-year, reflecting intensified trial activity.
The complement-therapeutics market is projected to expand at a ~12% CAGR through 2030, driven by growing recognition of the pathway’s role in autoimmune disease and increased venture capital inflows into biotech, which together bolster the commercial upside for DNTH’s pipeline.
For a deeper dive, you might explore ValueRay’s analyst notes on DNTH.
- DNTH103 clinical trial results impact stock
- Regulatory approval for DNTH103 crucial for revenue
- Competition in autoimmune drug market affects sales
- Funding for drug development influences operations
Piotroski VR‑10 (Strict)
1.0
| Net Income: -162.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA -3.42 > 1.0 |
| NWC/Revenue: 18.6k% < 20% (prev 4.21k%; Δ 14.4k% < -1%) |
| CFO/TA -0.24 > 3% & CFO -129.1m > Net Income -162.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.8m) vs 12m ago 7.88% < -2% |
| Gross Margin: 83.74% > 18% (prev 0.93%; Δ 8.28k% > 0.5%) |
| Asset Turnover: 0.45% > 50% (prev 1.67%; Δ -1.22% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z''
-9.39
| A: 0.71 (Total Current Assets 409.4m - Total Current Liabilities 30.7m) / Total Assets 530.9m |
| B: -0.63 (Retained Earnings -336.7m / Total Assets 530.9m) |
| C: -0.39 (EBIT TTM -174.4m / Avg Total Assets 452.5m) |
| D: -8.96 (Book Value of Equity -336.2m / Total Liabilities 37.5m) |
| Altman-Z'' Score: -9.39 = D |
Beneish M
-4.00
| DSRI: 0.39 (Receivables 102k/807k, Revenue 2.04m/6.24m) |
| GMI: 1.12 (GM 83.74% / 93.39%) |
| AQI: 0.92 (AQ_t 0.23 / AQ_t-1 0.24) |
| SGI: 0.33 (Revenue 2.04m / 6.24m) |
| TATA: -0.06 (NI -162.3m - CFO -129.1m) / TA 530.9m) |
| Beneish M-Score: -4.02 (Cap -4..+1) = AAA |
What is the price of DNTH shares?
As of April 06, 2026, the stock is trading at USD 86.00 with a total of 879,700 shares traded.
Over the past week, the price has changed by +8.24%, over one month by +40.00%, over three months by +133.13% and over the past year by +450.93%.
Over the past week, the price has changed by +8.24%, over one month by +40.00%, over three months by +133.13% and over the past year by +450.93%.
Is DNTH a buy, sell or hold?
Dianthus Therapeutics has received a consensus analysts rating of 4.83.
Therefore, it is recommended to buy DNTH.
- StrongBuy: 10
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DNTH price?
| Analysts Target Price | 127.8 | 48.5% |
Dianthus Therapeutics (DNTH) - Fundamental Data Overview
as of 04 April 2026
P/S = 2236.257 P/B = 9.0733
Revenue TTM = 2.04m USD
EBIT TTM = -174.4m USD
EBITDA TTM = -173.9m USD
Long Term Debt = 1.39m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 367k USD (from shortTermDebt, last quarter)
Debt = 1.39m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -49.7m USD (from netDebt column, last quarter)
Enterprise Value = 4.15b USD (4.55b + Debt 1.39m - CCE 404.3m)
Interest Coverage Ratio = unknown (Ebit TTM -174.4m / Interest Expense TTM 0.0)
EV/FCF = -32.10x (Enterprise Value 4.15b / FCF TTM -129.3m)
FCF Yield = -3.11% (FCF TTM -129.3m / Enterprise Value 4.15b)
FCF Margin = -6.35k% (FCF TTM -129.3m / Revenue TTM 2.04m)
Net Margin = -7.97k% (Net Income TTM -162.3m / Revenue TTM 2.04m)
Gross Margin = 83.74% ((Revenue TTM 2.04m - Cost of Revenue TTM 331k) / Revenue TTM)
Gross Margin QoQ = none% (prev 75.0%)
Tobins Q-Ratio = 7.82 (Enterprise Value 4.15b / Total Assets 530.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.39m)
Taxrate = 21.0% (US default 21%)
NOPAT = -137.8m (EBIT -174.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.32 (Total Current Assets 409.4m / Total Current Liabilities 30.7m)
Debt / Equity = 0.00 (Debt 1.39m / totalStockholderEquity, last quarter 493.4m)
Debt / EBITDA = 0.29 (negative EBITDA) (Net Debt -49.7m / EBITDA -173.9m)
Debt / FCF = 0.38 (negative FCF - burning cash) (Net Debt -49.7m / FCF TTM -129.3m)
Total Stockholder Equity = 417.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.88% (Net Income -162.3m / Total Assets 530.9m)
RoE = -38.85% (Net Income TTM -162.3m / Total Stockholder Equity 417.9m)
RoCE = -41.60% (EBIT -174.4m / Capital Employed (Equity 417.9m + L.T.Debt 1.39m))
RoIC = -32.97% (negative operating profit) (NOPAT -137.8m / Invested Capital 417.9m)
WACC = 9.83% (E(4.55b)/V(4.55b) * Re(9.83%) + D(1.39m)/V(4.55b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 188.8%
[DCF] Fair Price = unknown (Cash Flow -129.3m)
EPS Correlation: -41.37 | EPS CAGR: -9.09% | SUE: -1.79 | # QB: 0
Revenue Correlation: -41.90 | Revenue CAGR: -35.36% | SUE: -0.29 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.11 | Chg7d=+0.000 | Chg30d=-0.141 | Revisions Net=+1 | Analysts=7
EPS current Year (2026-12-31): EPS=-4.65 | Chg7d=+0.000 | Chg30d=-0.811 | Revisions Net=+1 | Growth EPS=-10.8% | Growth Revenue=-36.8%
EPS next Year (2027-12-31): EPS=-5.11 | Chg7d=+0.000 | Chg30d=-0.864 | Revisions Net=+1 | Growth EPS=-9.9% | Growth Revenue=+34.2%
[Analyst] Revisions Ratio: +0.33 (2 Up / 1 Down within 30d for Next Quarter)
External Resources